155 related articles for article (PubMed ID: 35763178)
41. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
42. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue.
Broun ER; Nichols CR; Kneebone P; Williams SD; Loehrer PJ; Einhorn LH; Tricot GJ
Ann Intern Med; 1992 Jul; 117(2):124-8. PubMed ID: 1318648
[TBL] [Abstract][Full Text] [Related]
43. Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines.
Schmidtova S; Kalavska K; Liskova V; Plava J; Miklikova S; Kucerova L; Matuskova M; Rojikova L; Cierna Z; Rogozea A; Konig H; Albany C; Mego M; Chovanec M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923996
[TBL] [Abstract][Full Text] [Related]
44. Biological markers of cisplatin resistance in advanced testicular germ cell tumours.
García-Velasco A; Durán I; García E; Tarón M; Ballestín C; Castellanos D; Cortés-Funés H; Paz-Ares L
Clin Transl Oncol; 2012 Jun; 14(6):452-7. PubMed ID: 22634534
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Beyer J; Metzner B; Ruther U; Harstrick A; Weissbach L; Kohrmann U; Verbeek W; Schmoll HJ
Ann Oncol; 1996 Jan; 7(1):31-4. PubMed ID: 9081388
[TBL] [Abstract][Full Text] [Related]
46. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours.
Nicolai N; Necchi A; Gianni L; Piva L; Biasoni D; Torelli T; Stagni S; Milani A; Pizzocaro G; Salvioni R
BJU Int; 2009 Aug; 104(3):340-6. PubMed ID: 19239440
[TBL] [Abstract][Full Text] [Related]
47. Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Schmoll HJ; Natt F; Knoche M; Beyer J; Souchon R
J Cancer Res Clin Oncol; 1994; 120(12):754-7. PubMed ID: 7798304
[TBL] [Abstract][Full Text] [Related]
48. Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors.
Shiraishi T; Nakamura T; Mikami K; Takaha N; Kawauchi A; Miki T
Int J Clin Oncol; 2009 Oct; 14(5):436-41. PubMed ID: 19856053
[TBL] [Abstract][Full Text] [Related]
49. Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry.
Fichtner A; Bohnenberger H; Elakad O; Richter A; Lenz C; Oing C; Ströbel P; Kueffer S; Nettersheim D; Bremmer F
World J Urol; 2022 Feb; 40(2):373-383. PubMed ID: 35084545
[TBL] [Abstract][Full Text] [Related]
50. High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors.
Lorch A; Neubauer A; Hackenthal M; Dieing A; Hartmann JT; Rick O; Bokemeyer C; Beyer J
Ann Oncol; 2010 Apr; 21(4):820-825. PubMed ID: 19822531
[TBL] [Abstract][Full Text] [Related]
51. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
Oechsle K; Kollmannsberger C; Honecker F; Mayer F; Waller CF; Hartmann JT; Boehlke I; Bokemeyer C;
Eur Urol; 2011 Oct; 60(4):850-5. PubMed ID: 21704446
[TBL] [Abstract][Full Text] [Related]
52. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
[TBL] [Abstract][Full Text] [Related]
53. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.
Feldman DR; Patil S; Trinos MJ; Carousso M; Ginsberg MS; Sheinfeld J; Bajorin DF; Bosl GJ; Motzer RJ
Cancer; 2012 Feb; 118(4):981-6. PubMed ID: 21792865
[TBL] [Abstract][Full Text] [Related]
54. Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours.
Bremmer F; Schallenberg S; Jarry H; Küffer S; Kaulfuss S; Burfeind P; Strauß A; Thelen P; Radzun HJ; Ströbel P; Honecker F; Behnes CL
Oncotarget; 2015 Oct; 6(32):33426-37. PubMed ID: 26451610
[TBL] [Abstract][Full Text] [Related]
55. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
[TBL] [Abstract][Full Text] [Related]
56. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.
Bajorin DF; Sarosdy MF; Pfister DG; Mazumdar M; Motzer RJ; Scher HI; Geller NL; Fair WR; Herr H; Sogani P
J Clin Oncol; 1993 Apr; 11(4):598-606. PubMed ID: 8386751
[TBL] [Abstract][Full Text] [Related]
57. Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial.
Necchi A; Lo Vullo S; Giannatempo P; Raggi D; Calareso G; Togliardi E; Crippa F; Pennati M; Zaffaroni N; Perrone F; Busico A; Colecchia M; Nicolai N; Mariani L; Salvioni R
Ann Oncol; 2017 Jun; 28(6):1346-1351. PubMed ID: 28383677
[TBL] [Abstract][Full Text] [Related]
58. Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors.
Bosl GJ; Geller NL; Vogelzang NJ; Carey R; Auman J; Whitmore WF; Herr H; Morse M; Sogani P; Chan E
J Clin Oncol; 1987 Mar; 5(3):436-40. PubMed ID: 2434627
[TBL] [Abstract][Full Text] [Related]
59. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
60. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA;
Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]